2023
Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options
Tuan J, Ogbuagu O. Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options. Expert Review Of Anti-infective Therapy 2023, 21: 565-570. PMID: 37067160, DOI: 10.1080/14787210.2023.2203913.Peer-Reviewed Original ResearchConceptsTreatment optionsMultidrug-resistant HIV infectionMultidrug-resistant HIVTreatment-emergent resistanceLimited treatment optionsClinical trial dataDrug-drug interactionsBreakthrough therapy designationHIV-1 capsid inhibitorsMechanism of actionAdherence supportCompanion drugsAntiretroviral agentsHIV infectionHIV treatmentClinical trialsLenacapavirPharmacodynamic propertiesDrug AdministrationExpert opinion sectionCapsid inhibitorsTrial dataU.S. FoodClinical usesYearly treatment
2022
Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)
Cespedes M, Das M, Hojilla JC, Blumenthal J, Mounzer K, Ramgopal M, Hodge T, Torres TS, Peterson C, Shibase S, Elliott A, Demidont AC, Callaghan L, Watson CC, Carter C, Kintu A, Baeten JM, Ogbuagu O. Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP). PLOS ONE 2022, 17: e0267780. PMID: 35657826, PMCID: PMC9165827, DOI: 10.1371/journal.pone.0267780.Peer-Reviewed Original ResearchConceptsClinical trialsHIV incidencePre-exposure prophylaxis clinical trialHispanic/LatinxRecruitment goalsGood participatory practice guidelinesOngoing phase 3 trialsHIV pre-exposure prophylaxisTransgender womenTransgender menPhase 3 trialPre-exposure prophylaxisCommunity-based clinicsFuture clinical trialsClinical trial numberEvidence-informed recommendationsLatinx MSMGender nonbinary individualsCisgender MSMNovel agentsPractice guidelinesStudy populationBlack MSMUS sitesTrials
2021
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial
Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, Wohl D, Gilson R, Shao Y, Ebrahimi R, Cox S, Kintu A, Carter C, Das M, Baeten JM, Brainard DM, Whitlock G, Brunetta JM, Kronborg G, Spinner CD, team D, Antinori A, Apea V, Asmuth D, Avery A, Benson P, Bergin C, Berhe M, Brar I, Brinson C, Brunetta J, Burack J, Campbell T, Cespedes M, Clarke A, Coleman M, Coll J, Casal M, Creticos C, Crofoot G, Cruickshank F, Cua E, Daar E, de Wet J, DeJesus E, Del Romero Guerrero J, Dinges W, Doblecki-Lewis S, Donovan T, Dosekun O, Flamm J, Gallant J, Gerstoft J, Gilson R, Gladstein J, Grant R, Grossberg R, Haas B, Halperin J, Hardy W, Hare C, Hassler S, Hengel R, Henry W, Hodge T, Hosek S, Hurt C, Iandiorio M, Jessen H, Kegg S, Knecht G, Kronborg G, Krznaric I, LaMarca A, Larsen C, Larsen O, Lazzarin A, Leen C, Lucasti C, Mallon P, Mannheimer S, Markowitz M, Martorell C, Mayer K, Mills A, Molina J, Morris S, Mounzer K, Nwokolo N, Ogbuagu O, Osiyemi O, Petroll A, Philibert P, Phoenix J, Pialoux G, Podzamczer D, Post F, Prins M, Ramgopal M, Rashbaum B, Reeves I, Richmond G, Rieger A, Ruane P, Salazar L, Scarsella A, Schembri G, Scott M, Shalit P, Sinclair G, Sobieszczyk M, Spinner C, Stephens J, Szabo J, Taylor S, Thompson M, Tremblay C, Trottier B, Voskuhl G, Wade B, Wohl D, Workowski K, Yawetz S, Young B. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet HIV 2021, 8: e397-e407. PMID: 34197772, DOI: 10.1016/s2352-3018(21)00071-0.Peer-Reviewed Original ResearchConceptsTenofovir disoproxil fumaratePre-exposure prophylaxisTenofovir alafenamideDisoproxil fumarateBone mineral densityHIV infectionPlacebo tabletsMineral densityHIV preventionHIV-1 pre-exposure prophylaxisTransgender womenAdult cisgender menNon-inferior efficacyWeek 96 resultsPrimary efficacy outcomeCisgender menPhase 3 trialIncident HIV infectionHIV-1 infectionNon-inferiority trialLong-term safetyMore weight gainRenal safety biomarkersSelf-reported sexual behaviorStudy medication
2018
Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus–infected patients compared to non-nucleoside and protease inhibitor–based regimens in a real-world clinical setting
Jacobson K, Ogbuagu O. Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus–infected patients compared to non-nucleoside and protease inhibitor–based regimens in a real-world clinical setting. Medicine 2018, 97: e13016. PMID: 30412140, PMCID: PMC6221636, DOI: 10.1097/md.0000000000013016.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsFemaleHIV InfectionsHumansMaleMiddle AgedRetrospective StudiesViral LoadConceptsVirologic suppressionInhibitor-based regimensAntiretroviral therapyMedian timeIntegrase strand transfer inhibitor (INSTI) classHuman immunodeficiency virus-infected patientsIntegrase inhibitor-based regimensMedian baseline CD4 countHuman immunodeficiency virus (HIV) patientsRetrospective single-center studyClinical settingProtease inhibitorsReal-world clinical settingART regimen typeVirologic suppression ratesBaseline CD4 countSingle-center studyVirus-infected patientsCells/μLCopies/mLStudy inclusion criteriaNon-nucleoside reverseRoutine clinical settingLower median timeART initiationPrevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings
Ogbuagu O, Marshall BDL, Tiberio P, Ogunbajo A, Barakat L, Montgomery M, Almonte A, Wray T, Williams EC, Edelman EJ, Chan PA. Prevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings. AIDS And Behavior 2018, 23: 190-200. PMID: 30145707, PMCID: PMC7020905, DOI: 10.1007/s10461-018-2260-9.Peer-Reviewed Original ResearchConceptsUnhealthy alcohol useUnhealthy alcoholPre-exposure prophylaxisUnhealthy substance useDrug useHIV acquisitionAlcohol useSubstance useHIV pre-exposure prophylaxisReal-world clinical settingProspective observational studyHIV-positive partnerHIV risk behaviorsStructured clinical assessmentFrequent drug usePrEP outcomesPrEP useRisk factorsClinical assessmentObservational studyPositive partnerReal-world settingMultivariate analysisYounger ageSexual partnersHIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system
Rutledge R, Madden L, Ogbuagu O, Meyer JP. HIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system. AIDS Care 2018, 30: 1282-1289. PMID: 29527934, PMCID: PMC6085161, DOI: 10.1080/09540121.2018.1447079.Peer-Reviewed Original ResearchConceptsPrEP implementation programsPre-exposure prophylaxisHIV risk behaviorsPrEP awarenessHIV pre-exposure prophylaxisRisk behaviorsPersonal HIV riskPrEP care continuumPrEP-eligible womenHepatitis C infectionPrimary care providersHIV risk perceptionUnsafe injection practicesMeeting eligibility criteriaPrison/jailCross-sectional surveyRecent transactional sexLifetime substance usePrEP eligibleC infectionEligible womenCare continuumHIV riskCare providersHigh risk
2017
Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations
Koff A, Goldberg C, Ogbuagu O. Condomless sex and HIV transmission among serodifferent couples: current evidence and recommendations. Annals Of Medicine 2017, 49: 534-544. PMID: 28409656, DOI: 10.1080/07853890.2017.1320423.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnti-HIV AgentsCondomsFemaleHIV InfectionsHIV SeropositivityHumansMalePre-Exposure ProphylaxisSexual PartnersUnsafe SexConceptsHIV transmissionSerodifferent couplesAntiretroviral therapyCondomless sexCondom useHIV-positive sexual partnerHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionPre-exposure prophylaxisHIV transmission riskUse of condomsInfected partnerHIV infectionHIV incidenceSexual transmissionHIV preventionPreventive benefitsVirus infectionCurrent evidencePrevention strategiesSexual partnersTransmission riskIndividual riskSexInfection
2016
Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients
Ogbuagu O. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert Review Of Anti-infective Therapy 2016, 14: 1113-1126. PMID: 27797606, DOI: 10.1080/14787210.2016.1255551.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHIV-1 infectionTenofovir alafenamideCombination antiretroviral medicationsEffective antiretroviral regimenKey drug interactionsSingle-tablet combinationAntiretroviral drug therapyTenofovir disoproxil fumarateDifferent patient populationsNon-nucleoside reverseClinical trial dataAntiretroviral regimenRenal safetyAntiretroviral medicationsCreatinine clearanceNeuropsychiatric toxicityDisoproxil fumaratePatient populationTreatment optionsDrug therapyDrug interactionsConference abstractsPubMed databaseTrial dataUS FDA